Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients

Inclusion criteria

• ✓. Signed and dated informed consent and willingness to comply with all study procedures and availability for the study duration,
• ✓. Histologically confirmed oesogastric, gastric, colon and/or rectum adenocarcinoma
• ✓. Patients with metastatic non-resectable (oesogastric or colorectal) or adjuvant (colorectal stage III) adenocarcinoma previously treated by fluoropyrimidines (5-FU or capecitabine),
• ✓. Age ≥18 years,
• ✓. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2,
• ✓. Patients who presented an episode of cardiac angina-related thoracic pain due to 5- FU or capecitabine (minimum 21 days \[3 weeks\] between event and inclusion) at least one of the following events:
• ✓. Contraindication to continue treatment with 5FU or capecitabine confirmed and documented by a cardiologist,CONFIDENTIAL Protocol ACOTAS version 1.5, 14/06/2021 Page 32 of 93
• ✓. Indication to receive trifluridine/tipiracil ± oxaliplatin considered better than absence of therapy (colo-rectal stage III) or the best alternative therapy (metastatic colo-rectal and oeso-gastric or gastric) confirmed by a Multidisciplinary Consultation Meeting

Exclusion criteria